Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with Lynestrenol.
The relationship of mastodynia with its endocrine environment, and treatment in a double-blind trial with Lynestrenol were investigated. Radioimmunological analysis of serum progesterone, estradiol, and prolactin carried out about 7 days before menstruation in 33 patients with mastodynia and 20 controls confirmed that progesterone is frequently decreased (p < .005) and prolactinemia increased in the patients with mastodynia compared with controls. In the double-blind trial, administration of Lynestrenol (10 mg/day from cycle Day 10-24) to 47 patients resulted in a significant (p < .05) clinical and thermographic improvement in 80% of the cases. An improvement was also found in 12 cases out of 23 after placebo. This beneficial effect of placebo was manifest independently of the variations in serum prolactin levels, while failures were more often evident in the presence of progesterone deficiency. It appears, that in the development of mastodynia, there is at least 1 functional lesion at 2 levels: progesterone deficiency was the most common, but excessive prolactin secretion was also involved though less frequently. Mastodynia is probably due to a number of factors in which progesterone deficiency predominates and where individual sensitivity plays an essential part.